A rare form of the thyroid gland cancer against the background of autoimmune thyroiditis

Cover Page

Cite item

Full Text

Abstract

Background: Sclerosing mucoepidermoid carcinoma of the thyroid gland was first reported in 1991. This type of a tumor may develop in connection with Hashimoto's thyroiditis. There are two variants of mucoepidermoid carcinoma of the thyroid gland: the normal and sclerosing types. Sclerosing mucoepidermoid carcinoma of the thyroid gland has recently been recognized by the World Health Organization as a separate disease. Сlinical case description: We present a clinical case of a 51-year-old woman who was observed for 2 years for autoimmune thyroiditis with nodulation. The patient had no symptoms or signs of compression. The level of thyroid–stimulating hormone was 15.8 (range 0.4–4.0), the level of antibodies to peroxidase was 150 IU/ml. Thyroid scintigraphy revealed a dominant cold node (1.5×2 cm) in the right lobe of the gland. During the control ultrasound examination of the neck, negative dynamics was observed, then a fine needle aspiration biopsy of the thyroid node was performed. A follicular tumor was found against the background of Hashimoto's thyroiditis, which was the reason for a timely treatment. In the described case, the patient underwent a total thyroidectomy without neck lymph node dissection, no postoperative radiotherapy or other auxiliary treatments were performed. A full-body scintigraphy showed no recurrence of the disease in 10 months after the initial treatment. Conclusion: Given the rarity of the disease and the impossibility to differentiate it from other thyroid tumor’s, a more thorough examination of the nearby lymphatic collectors is necessary to exclude metastatic lesions, and in the presence of altered lymph nodes, additional diagnosis by fine-needle aspiration biopsy with subsequent determination of the scope of surgical treatment and postoperative management of this category of patients is indicated.

About the authors

Evgeniy V. Ryabchenko

Regional Clinical Hospital No. 2

Author for correspondence.
Email: rev7512@mail.ru
ORCID iD: 0000-0003-4045-5053
SPIN-code: 4413-1478

MD, PhD

Russian Federation, Krasnodar

References

  1. Rhatigan RM, Roque JL, Bucher RL. Mucoepidermoid carcinoma of the thyroid gland. Cancer. 1977;39(1): 210–214. doi: 10.1002/1097-0142(197701)39:1<210::aid-cncr2820390133>3.0.co;2-h
  2. Sim SJ, Ro JY, Ordonez NG, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: Report of two patients, one with distant metastasis, and review of the literature. Hum Pathol. 1997;28(9):1091–1096. doi: 10.1016/s0046-8177(97)90064-2
  3. Chan JK, Albores-Saavedra J, Battifora H, et al. Sclerosing mucoepidermoid thyroid carcinoma with eosinophilia. A distinctive low-grade malignancy arising from the metaplastic follicles of Hashimoto’s thyroiditis. Am J SurgPathol. 1991;15(5):438–448.
  4. Hunt JL, Li Volsi VA, Barnes EL. p63 Expression in sclerosing mucoepidermoid carcinomas with eosinophilia arising in the thyroid. Mod Pathol. 2004;17(5):526–529. doi: 10.1038/modpathol.3800021
  5. Lai CY, Chao TC, Lin JD, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of thyroid gland in a male patient: A case report and literature review. Int J Clin Exp Pathol. 2015;8(5):5947–5951.
  6. Requena M. Conservative management of sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: 12 years follow-up after an atypical initial therapy. Adv Diabetes Endocrinol. 2017;2(1):2.
  7. Ames E, Campbell MJ, Afify A, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia: Cytologic characterization of a rare distinct entity in the thyroid. Diagn Cytopathol. 2018;46(7): 632–635. doi: 10.1002/dc.23914
  8. Shehadeh NJ, Vernick J, Lonardo F, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: A case report and review of the literature. Am J Otolaryngol. 2004;25(1):48–53. doi: 10.1016/s0196-0709(03)00096-6
  9. Son S-W, Lee K-H, Lee JH, Myong N-H. Mucoepidermoid carcinoma with distant metastases to the kidney, adrenal gland, skull and gluteus maximus muscle: A case report. Investig Magn Reson Imaging. 2016;(20):66–70. doi: 10.13104/imri.2016.20.1.66
  10. Healey WV, Perzin KH, Smith L. Mucoepidermoid carcinoma of salivary gland origin. Classification, clinical-pathologic correlation, and results of treatment. Cancer. 1970; 26(2):368–388. doi: 10.1002/1097-0142(197008)26:2<368::aid-cncr2820260219>3.0.co;2-k
  11. Pantola C, Kala S, Athar M, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: A cytological dilemma. J Cytol. 2016;33(1):37–39. doi: 10.4103/0970-9371.175511
  12. Toper MH, Sarioglu S. Molecular pathology of salivary gland neoplasms: Diagnostic, prognostic, and predictive perspective. Adv Anat Pathol. 2021;28(2):81–93. doi: 10.1097/PAP.0000000000000291
  13. Shafique K, Zhang PJ, Montone KT, et al. Pathologic grading of mucoepidermoid carcinomas of the salivary gland and its effect on clinicopathologic follow-up: An institutional experience. Hum Pathol. 2020;(98):89–97. doi: 10.1016/j.humpath.2020.02.001
  14. Baloch ZW, Asa SL, Barletta JA, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol. 2022;33(1):27–63. doi: 10.1007/s12022-022-09707-3
  15. Le HT, Nguyen TP, Hirokawa M, et al. Primary thyroid mucoepidermoid carcinoma (MEC) is clinically, prognostically, and molecularly different from sclerosing MEC with eosinophilia: A multicenter and integrated study. Endocr Pathol. 2023;34(1):100–111. doi: 10.1007/s12022-022-09741-1
  16. Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–1217. doi: 10.1056/NEJMoa1917239
  17. Loong HH, Du N, Cheng C, et al. KRAS G12C mutations in Asia: A landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res. 2020;9(5):1759. doi: 10.21037/tlcr-20-455
  18. Sheth H, Kumar P, Shreenivas A, et al. Excellent response with alpelisib and bicalutamide for advanced salivary duct carcinoma with PIK3CA mutation and high androgen receptor expression: A case report. JCO Precis Oncol. 2021;(5):PO.20.00436. doi: 10.1200/PO.20.00436
  19. Yoshimura T, Higashi S, Yamada S, et al. PCP4/PEP19 and HER2 are novel prognostic markers in mucoepidermoid carcinoma of the salivary gland. Cancers. 2021;14(1):54. doi: 10.3390/cancers14010054
  20. Di Villeneuve L, Souza IL, Tolentino FD, et al. Salivary gland carcinoma: Novel targets to overcome treatment resistance in advanced disease. Front Oncol. 2020;(10):580141. doi: 10.3389/fonc.2020.580141
  21. Terauchi M, Michi Y, Hirai H, et al. Prognostic factors in mucoepidermoid carcinoma of the minor salivary glands: A single-center retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;131(2):209–216. doi: 10.1016/j.oooo.2020.10.012

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Immunohistochemical study: а — tumour exhibiting combination of squamoid cells (large arrow), intermediate cells (small arrows) and cystic spaces (stars); б — cystic spaces lined by mucinous cells (arrows); в — small nests of tumour cells (small arrows) were seen against sclerotic background stroma, a lymphoid follicle was also seen (large arrow); г — intervening stroma between tumour cells showed eosinophil rich inflammatory infiltrate. Haematoxylin and eosin staining, ×400.

Download (1MB)
3. Fig. 2. Tumour cells exhibited cytoplasmic and membranous staining for (а) cytokeratin 5/6 and nuclear staining for (б) TTF-1 immunohistochemical stains. Periodic acid-Schiff-alcianblue special stain highlights intraluminal and intracytoplasmic mucin (в). ×400.

Download (1MB)
4. Fig. 3. Interface of tumour nests (arrows) with adjacent thyroid tissue (а). Adjacent thyroid tissue exhibited prominent Hurthle cell change (large arrow) and lymphoid aggregate (short arrow) (б). Haematoxylin and eosin staining, ×200.

Download (1MB)

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies